Last Updated : April 18, 2024
Details
FilesGeneric Name:
everolimus
Project Status:
Active
Therapeutic Area:
Renal angiomyolipoma associated with tuberous sclerosis complex
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Non-Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
SX0814-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Renal angiomyolipoma associated with TSC.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 12-Jul-23 |
|---|---|
| Call for patient/clinician input closed | 01-Sep-23 |
| Call for industry input open | 13-Jul-23 |
| Call for industry input closed | 01-Sep-23 |
| Submission received | 06-Jul-23 |
| Clarification: - Patient input submission received from TSC Canada | |
| Review initiated | 18-Jul-23 |
| Expert committee meeting (initial) | 01-Feb-24 |
| Draft recommendation posted for stakeholder feedback | 28-Feb-2024 |
| End of feedback period | 13-Mar-2024 |
Files
Last Updated : April 18, 2024